Evidence map›Paper›PMID 42610710›Full record

ArticleToxicological sciences : an official journal of the Society of Toxicology2026

Detecting drug-induced nephrotoxicity using simultaneous label-free autofluorescence multiharmonic microscopy.

Aneesh Alex, Jindou Shi, Eric J Chaney, Minh Doan, Ciarán P Fisher, Leslie Obert, Crysthiane Ishiy, Alexander Ho, Darold R Spillman, Marina Marjanovic and 4 more

Abstract read
In one paragraph

Article in Toxicological sciences : an official journal of the Society of Toxicology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Aneesh AlexGSK Center for Optical Molecular Imaging, Beckman Institute for Advanced Science and Technology, University of Illinois Urbana-Champaign, Urbana, IL 61801, United States.ORCID 0000-0001-8652-307X
Jindou ShiGSK Center for Optical Molecular Imaging, Beckman Institute for Advanced Science and Technology, University of Illinois Urbana-Champaign, Urbana, IL 61801, United States.
Eric J ChaneyGSK Center for Optical Molecular Imaging, Beckman Institute for Advanced Science and Technology, University of Illinois Urbana-Champaign, Urbana, IL 61801, United States.
Minh DoanPre-Clinical Sciences, GSK plc, Collegeville, PA 19426, United States.
Ciarán P FisherPre-Clinical Sciences, GSK plc, Stevenage, SG1 2NY, United Kingdom.
Leslie ObertPre-Clinical Sciences, GSK plc, Collegeville, PA 19426, United States.ORCID 0000-0001-9788-2908
Crysthiane IshiyPre-Clinical Sciences, GSK plc, Stevenage, SG1 2NY, United Kingdom.
Alexander HoGSK Center for Optical Molecular Imaging, Beckman Institute for Advanced Science and Technology, University of Illinois Urbana-Champaign, Urbana, IL 61801, United States.
Darold R SpillmanGSK Center for Optical Molecular Imaging, Beckman Institute for Advanced Science and Technology, University of Illinois Urbana-Champaign, Urbana, IL 61801, United States.
Marina MarjanovicGSK Center for Optical Molecular Imaging, Beckman Institute for Advanced Science and Technology, University of Illinois Urbana-Champaign, Urbana, IL 61801, United States.
Jan RogerPre-Clinical Sciences, GSK plc, Stevenage, SG1 2NY, United Kingdom.
M Reid GrosecloseGSK Center for Optical Molecular Imaging, Beckman Institute for Advanced Science and Technology, University of Illinois Urbana-Champaign, Urbana, IL 61801, United States.
Steve R HoodGSK Center for Optical Molecular Imaging, Beckman Institute for Advanced Science and Technology, University of Illinois Urbana-Champaign, Urbana, IL 61801, United States.
Stephen A BoppartGSK Center for Optical Molecular Imaging, Beckman Institute for Advanced Science and Technology, University of Illinois Urbana-Champaign, Urbana, IL 61801, United States.ORCID 0000-0002-9386-5630

Funding

The Center for Label-free Imagingand Multiscale Biophotonics (CLIMB)P41EB031772 · NIBIB · UNIVERSITY OF ILLINOIS AT URBANA-CHAMPAIGN · PI Stephen A Boppart · 2022 to 2026
$7.6M
NIBIB NIH HHS P41 EB031772NIH/NIBIB Center for Label-free Imaging in Multiscale Biophotonics P41EB031772
6 · The paper itself

Abstract

Drug-induced nephrotoxicity (DIN) is a major cause of drug development failure, yet many cases are detected only late in clinical trials or after approval. Conventional methods to detect DIN often lack sensitivity and specificity, particularly for early or region-specific kidney injury. Here, we evaluate Simultaneous Label-free Autofluorescence Multiharmonic (SLAM) microscopy as a rapid, label-free imaging approach to quantify kidney microstructural and functional metabolic changes associated with DIN. SLAM simultaneously captures endogenous NAD(P)H and FAD autofluorescence, collagen-derived second harmonic generation, and third-harmonic generation from structural interfaces. SLAM images were acquired from the cortex and outer medulla (OM) of rat kidneys after cisplatin dosing at days 1, 6, and 29 post-administration. Imaging revealed region-specific injury, with the OM showing greater sensitivity to DIN than the cortex. The most prominent changes-tubular degeneration and hyaline casts-peaked at day 6, whereas tubular dilation and fibrosis-related features persisted to day 29. Feature-based classification captured these spatial and temporal patterns, achieving higher balanced accuracy in the OM (0.944) than in the cortex (0.860). Key model drivers included granularity and inter-channel correlations, underscoring the value of multi-channel SLAM data. Overall, these results demonstrate the potential of SLAM microscopy for sensitive, region-specific detection and characterization of DIN in preclinical safety studies. SLAM microscopy provides a rapid, label-free way to detect, localize, and classify drug-induced nephrotoxicity with improved sensitivity and regional specificity, potentially strengthening preclinical kidney safety screening and reducing late-stage development failures.

Indexed as

CisplatinKidneyKidney DiseasesOptical ImagingAnimalsMaleMicroscopy, FluorescenceRatsRats, Sprague-DawleyCisplatincisplatindrug-induced nephrotoxicitylabel-free imagingnew approach methodologiesSLAM

Identifiers

PMID42610710
PMCPMC13537822

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.